<DOC>
	<DOCNO>NCT01702441</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics , pharmacodynamics , pilot efficacy multiple ascend dose level AKB-9778 give subcutaneous injection daily 28 day patient diabetic macular edema ( DME ) .</brief_summary>
	<brief_title>Safety Pilot Efficacy AKB-9778 Subjects With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>The following abbreviated list inclusion criterion : Adults 18 80 year age , inclusive Diagnosis diabetes mellitus ( type 1 type 2 ) Decrease vision determine primarily result DME study eye Definite Retinal thicken due diffuse DME involve center macula study eye Mean central subfield thickness least 325 µm OCT study eye Early Treatment Diabetic Retinopathy Study ( ETDRS ) letter score BCVA ≤ 70 ( 20/40 ) study eye The following abbreviated list exclusion criterion : Hemoglobin A1C ( HbA1C ) ≥ 11.5 % History follow study eye ( however , follow exclusionary fellow eye ) : 1 . Panretinal scatter photocoagulation ( PRP ) focal laser within 12 week prior Screening 2 . Prior par plana vitrectomy within 12 week prior Screening 3 . Any ocular surgery within 12 week prior Screening 4 . YAG capsulotomy within 7 day prior Screening 5 . Prior intravitreal , subtenon , periocular steroid therapy within 3 month prior Screening prior treatment intravitreal antiVEGF treatment within 1 month Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>